Troikaa Pharmaceuticals

Last updated
Troikaa Pharmaceuticals Ltd.
Company type Private
Industry Pharmaceuticals
Founded1983
FounderMr. Rajni V. Patel
Headquarters
Ahmedabad, Gujarat
,
India
Area served
Worldwide
Key people
  • Dr. Ketan R. Patel (Chairman & managing director)
  • Mr. Milan R. Patel (Joint Managing Director)
Products Pharmaceuticals, Branded and Generic drugs,
Number of employees
2300+ (2019)
Website www.troikaa.com

Troikaa Pharmaceuticals is an Indian multinational pharmaceutical company headquartered in Ahmedabad city of Gujarat, India. [1] It is a public unlisted company and is classified as company limited by shares. [2] [3]

Contents

History

Troikaa Pharmaceuticals limited was established in 1983 in Ahmedabad, Gujarat by Rajni V. Patel, one of the few pharmacy graduates, of the first batch of L. M. College of Pharmacy, Ahmedabad in 1950. Ketan R. Patel is the current Chairman & Managing Director of the company. According to article, he was named as “India’s pain killer” for inventing world's first painless diclofenac injection, which helps alleviate acute pain and inflammation. Milan R. Patel is Joint Managing Director of the company.

In May 2020, Troikaa received US Patent for one of its products 'Dynapar QPS'. [4]

Operations

Troikaa has three manufacturing facilities in Gujarat and Uttarakhand certified by ISO 9001:2000 and WHO GMP (The World Health Organization for following Good Manufacturing Practices). Company has six marketing divisions & strength of more than 2300 employees. Company has presence in more than 70 countries. [5]

Troikaa secures its innovations related to Novel Drug Delivery systems through Patent co-operation treaty in more than 100 countries of the world. [6] [7]

Litigation

In 2016, Troikaa Pharmaceuticals filed petition in Delhi High Court seeking license cancellation of Diclofenac Sodium Injection 75 mg/ml, manufactured by Themis Medicare Pvt Ltd and marketed by Novartis India Ltd. under the brand name Voveran 1ml. [8] [9]

Troikaa Pharmaceuticals claimed that the diclofenac sodium 75 mg/ml injection contained Transcutol-P which caused damage to the kidneys. In July 2018, India's Drug Regulator canceled the license granted to M/S Themis Medicare for the sale of Diclofenac injection 75 mg/ml containing Transcutol-P. [10] [11]

In 2012, Troikaa Pharmaceuticals suits a patent infringement in Ahmedabad district court against Ahmedabad-based Lincoln Pharmaceuticals and Delhi-based Akums Drug & Pharmaceuticals Ltd, saying the two companies had infringed upon its patented high concentration, low viscosity diclofenac injection. The case was continued by Gujarat High Court and ordered to Akums Drugs not to infringe as per the patent specification and dismissed Linclon Pharma's appeal. [12]

In 2008, Troikaa filed a suit for infringement of design against a company manufacturing D’ shaped tablets. The company had challenged that Troikaa's D-shaped tablet registration was invalid. The suit was transferred to the High Court of Gujarat and later in its first case under the Designs Act, the High Court decided in favor of the Troikaa. [13]

Awards & honors

Related Research Articles

<span class="mw-page-title-main">Novartis</span> Swiss-American multinational pharmaceutical corporation

Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022.

<span class="mw-page-title-main">Generic drug</span> Pharmaceutical equivalent to a brand-name product

A generic drug is a pharmaceutical drug that contains the same chemical substance as a drug that was originally protected by chemical patents. Generic drugs are allowed for sale after the patents on the original drugs expire. Because the active chemical substance is the same, the medical profile of generics is equivalent in performance compared to their performance at the time when they were patented drugs. A generic drug has the same active pharmaceutical ingredient (API) as the original, but it may differ in some characteristics such as the manufacturing process, formulation, excipients, color, taste, and packaging.

<span class="mw-page-title-main">Diclofenac</span> Nonsteroidal anti-inflammatory drug


Diclofenac, sold under the brand name Voltaren, among others, is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain and inflammatory diseases such as gout. It is taken by mouth or rectally in a suppository, used by injection, or applied to the skin. Improvements in pain last for as much as eight hours. It is also available in combination with misoprostol in an effort to decrease stomach problems.

<span class="mw-page-title-main">Cipla</span> Indian multinational pharmaceutical company

Cipla Limited is an Indian multinational pharmaceutical company, headquartered in Mumbai. Cipla primarily develops medication to treat respiratory disease, cardiovascular disease, arthritis, diabetes, depression, and other medical conditions.

The pharmaceutical industry in India was valued at an estimated US$42 billion in 2021 and is estimated to reach $130 billion by 2030. India is the world's largest provider of generic medicines by volume, with a 20% share of total global pharmaceutical exports. It is also the largest vaccine supplier in the world by volume, accounting for more than 60% of all vaccines manufactured in the world. Indian pharmaceutical products are exported to various regulated markets including the US, UK, European Union and Canada.

Torrent Pharmaceuticals Ltd is an Indian multinational pharmaceutical company, owned by the Rs 37,000 crore Torrent Group and headquartered in Ahmedabad. It was promoted by U. N. Mehta, initially as Trinity Laboratories Ltd, and was later renamed Torrent Pharmaceuticals Ltd.

<span class="mw-page-title-main">Zydus Lifesciences</span> Indian multinational pharmaceutical company

Zydus Lifesciences Limited, formerly known as Cadila Healthcare Limited, is an Indian multinational pharmaceutical company headquartered in Ahmedabad, which is primarily engaged in the manufacture of generic drugs. The company ranked 100th in the Fortune India 500 list in 2020.

<span class="mw-page-title-main">Glatiramer acetate</span> Medication

Glatiramer acetate, sold under the brand name Copaxone among others, is an immunomodulator medication used to treat multiple sclerosis. Glatiramer acetate is approved in the United States to reduce the frequency of relapses, but not for reducing the progression of disability. Observational studies, but not randomized controlled trials, suggest that it may reduce progression of disability. While a conclusive diagnosis of multiple sclerosis requires a history of two or more episodes of symptoms and signs, glatiramer acetate is approved to treat a first episode anticipating a diagnosis. It is also used to treat relapsing-remitting multiple sclerosis. It is administered by subcutaneous injection.

Evergreening is any of various legal, business, and technological strategies by which producers extend the lifetime of their patents that are about to expire in order to retain revenues from them. Often the practice includes taking out new patents, or by buying out or frustrating competitors, for longer periods of time than would normally be permissible under the law. Robin Feldman, a law professor at UC Law SF and a leading researcher in intellectual property and patents, defines evergreening as "artificially extending the life of a patent or other exclusivity by obtaining additional protections to extend the monopoly period."

<span class="mw-page-title-main">Sun Pharma</span> Indian multinational pharmaceutical company

Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in more than 100 countries across the globe. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world. The products cater to a vast range of therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals. Its active pharmaceutical products include baricitinib, brivaracetam, and dapaglifozin.

Pankaj Ramanbhai Patel is an Indian billionaire businessman, and the chairman of Zydus Lifesciences, the fifth largest pharmaceutical company in India.

<span class="mw-page-title-main">Indravadan Modi</span> Indian businessman

Indravadan Ambalal Modi was an Indian pharmaceuticals industrialist who founded Cadila Pharmaceuticals in Ahmedabad. He is popularly known as the 'Medicine Man of India' for his contribution to the pharmaceutical industry of India post independence.

<i>Novartis v. Union of India & Others</i>

Novartis v. Union of India & Others is a landmark decision by a two-judge bench of the Indian Supreme Court on the issue of whether Novartis could patent Gleevec in India, and was the culmination of a seven-year-long litigation fought by Novartis. The Supreme Court upheld the Indian patent office's rejection of the patent application.

<span class="mw-page-title-main">Cadila Pharmaceuticals</span> Indian pharmaceutical company

Cadila Pharmaceuticals is an Indian multinational pharmaceutical company based in Ahmedabad. The company's operations focus on manufacturing products ranging from active pharmaceutical intermediates, finished formulations, food supplements, biotechnology products and pharmaceutical machinery.

<span class="mw-page-title-main">Ceritinib</span> ALK inhibitor for treatment of non-small-cell lung cancer

Ceritinib is a prescription-only drug used for the treatment of non-small cell lung cancer (NSCLC). It was developed by Novartis and received FDA approval for use in April 2014..Ceritinib is also sold under the brand name Spexib in few countries by Novartis.

Alembic Pharmaceuticals Ltd. is an Indian multinational pharmaceutical company headquartered in Vadodara. It is involved in manufacture of pharmaceutical products, pharmaceutical substances and intermediates. It is also termed to be a market leader in macrolides segment of anti-infective drugs in India.

<span class="mw-page-title-main">Ketan R. Patel</span> Indian entrepreneur, scientist and pharmacist

Dr. Ketan R. Patel is an Indian pharmacist, Innovator, and serves as the Chairman & Managing Director of Troikaa Pharmaceuticals Ltd., a pharmaceutical company headquartered in Gujarat, India.

<span class="mw-page-title-main">Natco Pharma</span> Indian pharmaceutical company

Natco Pharma is an Indian multinational pharmaceutical company based in Hyderabad. The company manufactures finished dosage formulations active pharmaceutical ingredients and crop health science products, and also provides contract manufacturing services. It is a major producer of branded oncology medicines and hepatitis C drugs. The company specialises in producing complex medicines at affordable prices. In 2019, Natco launched its crop health sciences division.

<span class="mw-page-title-main">Proprietary drug</span>

Proprietary drug are chemicals used for medicinal purposes which are formulated or manufactured under a name protected from competition through trademark or patent. The invented drug is usually still considered proprietary even if the patent expired. When a patent expires, generic drugs may be developed and released legally. Some international and national governmental organizations have set up laws to enforce intellectual property to protect proprietary drugs, but some also highlight the importance of public health disregarding legal regulations. Proprietary drugs affect the world in various aspects including medicine, public health and economy.

The Pharmaceutical industry in Gujarat ranks number one in India with a 33% share in drug manufacturing and a 28% share in drug exports. The state has 130 USFDA certified drug manufacturing facilities. Ahmedabad and Vadodara are considered as pharmaceutical hubs as there are many big and small pharma companies established in these cities.

References

  1. ↑ "National Technology Day Celebration". pib.nic.in.
  2. ↑ Das, Sohini (1 October 2014). "Drug cos bet on NDDS for better price, market share". Business Standard India. Archived from the original on 17 June 2019. Retrieved 19 October 2023.
  3. ↑ "Troikaa's Dynapar QPS bags National Award". BPD. 10 June 2015. Archived from the original on 17 June 2019. Retrieved 19 October 2023.
  4. ↑ Correspondent, Special (21 May 2020). "Troikaa Pharma receives U.S. patent for Dynapar QPS". The Hindu. Archived from the original on 12 June 2020. Retrieved 19 October 2023.
  5. ↑ Reporter, B. S. (13 September 2010). "Troikaa Pharma gets patent approval for Dynapar AQ in CIS". Business Standard India. Archived from the original on 17 May 2021. Retrieved 19 October 2023.
  6. 1 2 Reporter, B. S. (22 May 2015). "Troikaa Pharma commences work on Sanand plant; to make Dynapar". Business Standard India. Archived from the original on 30 August 2019. Retrieved 19 October 2023.
  7. ↑ Reporter, B. S. (2 December 2009). "Troikaa gets Australian patent for Dynapar AQ". Business Standard India. Archived from the original on 30 August 2019. Retrieved 19 October 2023.
  8. ↑ Raghavan, Prabha (19 May 2016). "Indian pharma company may sue drug controller over safety of Novartis painkiller". The Economic Times. Archived from the original on 1 August 2017. Retrieved 19 October 2023.
  9. ↑ Thacker, Teena (11 July 2018). "Drug regulator orders recall of Novartis's painkiller diclofenac". livemint.com. Archived from the original on 13 August 2022. Retrieved 19 October 2023.
  10. ↑ India, Press Trust of (12 July 2018). "Drug regulator cancels licence for Diclofenac sold by Novartis". Business Standard India. Archived from the original on 17 June 2019. Retrieved 19 October 2023.
  11. ↑ "'Novartis, Themis use unsafe ingredient' - BUSINESS & ECONOMY - News | News Syndication | Content Syndication". dnasyndication.com. Archived from the original on 2023-10-20. Retrieved 2023-10-19.
  12. ↑ Dutta, Vishal (30 April 2012). "HC grants relief to Troikaa in patent case; restrains two firms from selling Dynapar injections". The Economic Times. Archived from the original on 20 October 2023. Retrieved 19 October 2023.
  13. ↑ Reddy, Prashant. "Gujarat High Court grants interim injunction in Designs Case". SpicyIP. Archived from the original on 2021-01-31. Retrieved 2023-10-19.
  14. ↑ "Technology Development Board 20th Annual Report 2015-16" (PDF). tdb.gov.in. Govet of India. Archived (PDF) from the original on 2022-07-09. Retrieved 2023-10-19.
  15. ↑ "National Technology Day Celebration". pib.nic.in. Archived from the original on 2016-08-20. Retrieved 2023-10-19.
  16. ↑ "Troikaa bags recognition from Govt of India". BPD. 1 March 2018.
  17. ↑ "Troikaa wins award for IP Excellence". Daily News and Analysis . Ahmedabad. Zee Media. 12 Dec 2018. p. 4.
  18. ↑ "Troika receiving the IPA-ACG innovation in Solid Dosage form Award". No. July 2015. Ahmedabad: Pharma Times. 7 July 2015. p. 9.
  19. ↑ "DSIR : Department of Scientific and Industrial Research". www.dsir.gov.in. Archived from the original on 2023-09-14. Retrieved 2023-10-19.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.